Our board of directors considered the fact that we were in the early stages of considering strategic alternatives that could create more value
for shareholders than the Tang Capital proposal, that the directors believed that continuing to execute on our strategic plan, which included conducting the PROSPECT II clinical trial and continuing to develop our Renova ™ Cortical Stimulation System, could ultimately create more value
for shareholders than the Tang Capital proposal, and that management had
prepared an informal
liquidation analysis which showed that the estimated
liquidation value of Northstar at that time was greater than the price in the Tang Capital proposal.